Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | HR4RB | — |
A 34 months old female patient received an adult dose of Havrix; A 34 months old female patient received an adult dose of Havrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 34-month-old female patient who received HAV (Havrix adult) (batch number HR4RB, expiry date 18-DEC-2025) for prophylaxis. On an unknown date, the patient received Havrix adult. On an unknown date, an unknown time after receiving Havrix adult, the patient experienced adult product administered to child (Verbatim: A 34 months old female patient received an adult dose of Havrix) and overdose (Verbatim: A 34 months old female patient received an adult dose of Havrix). The outcome of the adult product administered to child and overdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 16-JAN-2025 A registered nurse called to report that they administered an adult dose of Havrix to a 34 months old female patient, which led to adult product administered to child and overdose. And enquiring whether this dose count as valid.